VivoSim LabsFRA:4OR 39 Debt-to-Equity is 0.13 as of Dec. 2025, which is at its 10-year median of 0.13. GuruFocus rates FRA:4OR with a GF Score™ of 39/100 and a GF Value™ of €9.41. The stock has 4 warning signs investors should review. Among 965 Biotechnology companies, VivoSim Labs ranks better than 55.65% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for VivoSim Labs's Debt-to-Equity or its related term are showing as below:
FRA:4OR'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.07 Med: 0.13 Max: 2.91
Current: 0.13
During the past 13 years, the highest Debt-to-Equity Ratio of VivoSim Labs was 2.91. The lowest was 0.07. And the median was 0.13.
FRA:4OR's Debt-to-Equity is ranked better than 55.65% of 965
companies
in the Biotechnology industry
Industry Median: 0.16
vs FRA:4OR: 0.13
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
VivoSim Labs Debt-to-Equity Related Terms
VivoSim Labs Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for VivoSim Labs's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4OR vs SLXN, CDT, CLDI: Debt-to-Equity Comparison
For the Biotechnology subindustry, VivoSim Labs's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VivoSim Labs Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, VivoSim Labs's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where VivoSim Labs's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VivoSim Labs (FRA:4OR) has a Debt-to-Equity of 0.13 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on VivoSim Labs and its competitors. This is near median its historical median of 0.13. Over the past decade, VivoSim Labs' Debt-to-Equity has ranged from 0.07 to 2.91. According to the industry distribution chart, VivoSim Labs ranks #428 out of 965 companies in the Biotechnology industry, placing it in the top 44.4%.
Is VivoSim Labs' Debt-to-Equity too high?
VivoSim Labs' current Debt-to-Equity of 0.13 is near median its 10-year median of 0.13. Over the past 10 years, this metric has ranged from a low of 0.07 to a high of 2.91. The Biotechnology industry median Debt-to-Equity is 0.16. VivoSim Labs' value of 0.13 is 18.8% below this industry median. Based on the distribution chart, VivoSim Labs ranks #428 out of 965 companies in the Biotechnology industry, which is above the industry midpoint. Overall, VivoSim Labs has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does VivoSim Labs' Debt-to-Equity compare to SLXN and CDT?
According to the Biotechnology industry distribution chart, VivoSim Labs ranks #428 out of 965 companies for Debt-to-Equity. This puts VivoSim Labs in the upper half of its industry. The industry median Debt-to-Equity is 0.16. VivoSim Labs' value of 0.13 is 18.8% below this benchmark. Historically, VivoSim Labs' own Debt-to-Equity has ranged from 0.07 to 2.91 over the past decade. While the company's 10-year median is 0.13 vs. the industry median of 0.16, VivoSim Labs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. VivoSim Labs's current Debt-to-Equity of 0.13 is 18.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on VivoSim Labs and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VivoSim Labs's current Debt-to-Equity is 0.13, which is near median its own 10-year median of 0.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VivoSim Labs stock overvalued right now?
VivoSim Labs (FRA:4OR) has a current Debt-to-Equity of 0.13. The stock's GF Value™ is €9.41, compared to a current price of €3.49 — trading 62.9% below its estimated fair value. The current Debt-to-Equity is 0.13, which is near median its 10-year median of 0.13 and 18.8% below the Biotechnology industry median of 0.16. VivoSim Labs' overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For VivoSim Labs (FRA:4OR), the current Debt-to-Equity is 0.13 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is VivoSim Labs (FRA:4OR) Overvalued in 2026?
Based on GuruFocus' analysis, VivoSim Labs stock appears to be undervalued.
The current stock price of €3.49 is trading 62.9% below its estimated GF Value™ of €9.41.
Key valuation signals for FRA:4OR:
Debt-to-Equity: 0.13 (near median its 10-year median of 0.13)
GF Value™: €9.41 vs. price of €3.49 (62.9% below fair value)
Industry Position: 18.8% below the Biotechnology median (#428 of 965)
No single metric tells the full story. See the FRA:4OR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
39GF Score
Get the complete analysis for FRA:4OR
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4OR has been successfully added to your 
